Rxi Pharmaceuticals Corp. negotiated an exclusive option to acquire privately held cancer immunotherapy developer Mirimmune Inc. The all-stock deal will give Mirimmune shareholders nearly a 20 percent equity stake in Rxi should it close as expected and could provide it further equity-based payments upon hitting certain undisclosed milestones.